Vincerx Pharma Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Vincerx Pharma şirketinin kazançlarının yıllık 15.6% oranında düşmesi, yıllık gelirinin ise yıllık 79.1% oranında artması bekleniyor. EPS'nin yıllık 13.7% oranında büyümesi bekleniyor.

Anahtar bilgiler

-15.6%

Kazanç büyüme oranı

13.7%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	79.1%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	13 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:VINC - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	0	-42	-40	N/A	1
12/31/2025	N/A	-27	-27	N/A	3
12/31/2024	N/A	-29	-6	N/A	3
9/30/2024	N/A	-27	-28	-28	N/A
6/30/2024	N/A	-28	-28	-28	N/A
3/31/2024	N/A	-38	-35	-35	N/A
12/31/2023	N/A	-40	-40	-40	N/A
9/30/2023	N/A	-46	-46	-46	N/A
6/30/2023	N/A	-54	-54	-54	N/A
3/31/2023	N/A	-61	-58	-58	N/A
12/31/2022	N/A	-63	-60	-60	N/A
9/30/2022	N/A	-58	-57	-57	N/A
6/30/2022	N/A	-66	-53	-53	N/A
3/31/2022	N/A	-49	-45	-45	N/A
12/31/2021	N/A	-39	-39	-33	N/A
9/30/2021	N/A	-49	-29	-24	N/A
6/30/2021	N/A	-25	-19	-14	N/A
3/31/2021	N/A	-23	-11	-6	N/A
12/31/2020	N/A	-17	-2	-2	N/A
9/30/2020	N/A	0	0	0	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: VINC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: VINC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: VINC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: VINC gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: VINC gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: VINC 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Vincerx Pharma Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 14% to US$6.00

Price target increased by 35% to US$9.00

Price target decreased to US$8.40

Price target decreased to US$12.60

Price target decreased to US$21.33

Price target decreased to US$23.86

Recent updates

Vincerx Pharma, Inc. Receives Extension from Nasdaq Stock Market LLC to Meet the Exchange's Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Market cap size

Price target decreased by 14% to US$6.00

Vincerx Pharma, Inc. Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline

Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely

New major risk - Financial position

Insufficient new directors

New major risk - Negative shareholders equity

New minor risk - Shareholder dilution

Vincerx Pharma, Inc. has completed a Follow-on Equity Offering.

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering.

Vincerx Pharma, Inc., Annual General Meeting, May 23, 2024

New minor risk - Market cap size

Vincerx Pharma, Inc. Presents Positive Preliminary Phase 1 Data for Vip236 and Updates on Pipeline Progress At the American Association for Cancer Research (Aacr) Annual Meeting 2024

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 35% to US$9.00

New major risk - Share price stability

Vincerx Pharma, Inc. Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

New major risk - Financial position

New major risk - Revenue and earnings growth

Vincerx Pharma Receives Non-Compliance Notice from the Nasdaq Stock Market

Vincerx Pharma Receives Non-Compliance Notice from the Nasdaq Stock Market

Vincerx Pharma, Inc. Announces FDA Clearance of IND for VIP943

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

New major risk - Financial position

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Vincerx Pharma, Inc. Announces Resignation of Board of Directors

Vincerx Pharma Announces Fda Safe to Proceed Letter for Investigational New Drug (Ind) Application for Its <Alpha>V<Beta>3 Small Molecule-Drug Conjugate (Smdc) Vip236

Price target decreased to US$8.40

Vincerx Pharma, Inc. Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Price target decreased to US$12.60

High number of new and inexperienced directors

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Founder recently bought US$56k worth of stock

Vincerx Pharma, Inc.(NasdaqCM:VINC) dropped from Russell 2000 Growth Index

Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?

Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

Vincerx Pharma, Inc. Announces Departure of Hermes Garban as Chief Medical Officer, Effective on or Before August 6, 2022

Vincerx Pharma, Inc. Provides Clinical Updates

Price target decreased to US$21.33

High number of new and inexperienced directors

Vincerx, Inc., Annual General Meeting, May 26, 2022

Price target decreased to US$23.86

Price target decreased to US$26.57

High number of new and inexperienced directors

Founder recently bought US$65k worth of stock

Vincerx Pharma, Inc. Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

Independent Director recently bought US$126k worth of stock

Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021

Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors

Vincerx Pharma doses first patient in early-stage VIP152 cancer study

Independent Director has left the company

Vincerx Pharma, Inc. Announces Management Appointments

Vincerx Pharma, Inc., Annual General Meeting, May 13, 2021

Vincerx, Inc. Announces Executive Changes

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin